#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Immune appoints Gad Berdugo as CFO

Share on Twitter Share on LinkedIn
Staff writer | New York, N.Y., USA | January 22, 2015
Gad BerdugoImmune Pharmaceuticals Inc. appointed Gad Berdugo as EVP and CFO and Cameron Durrant as lead independent director and chairman of the compensation committee.
Prior to his appointment, Mr. Berdugo was a Managing Director and Head of the Global Life Sciences at Tegris Advisors, a New York City based investment-banking boutique.

He brings over 20 years of experience in investment management and banking, strategic financial advisory and business and corporate development in the biomedical industry.

He was previously the Founder and Managing Partner of Explorium Capital.

From 2001 to 2008 he served as Director at Lazard Asset Management Group, managing healthcare investments across a diverse range of Funds.

Mr. Berdugo started his career at Abbott and then at Baxter Healthcare, where he was Director of Global Business Development for the Bio-Pharmaceutical Group.

Mr. Berdugo received his M.B.A. from H.E.C. School of Management in Paris and studied at Northwestern Kellogg School of Management, his M.Sc. in Biochemical Engineering from University College London and his B.Sc. with Honors, in Biotechnology from Imperial College London.

Dr. Durrant is an entrepreneur, board member and former CEO/CFO and physician.

He has served as board chairman and director and operated as CEO or interim CEO, as well as CFO, for both private and public companies.

He has been a senior executive with US and Global Profit and Loss responsibilities and has also been at several blue-chip pharmaceutical companies, including most recently Worldwide Vice President at Johnson & Johnson and previously as Vice President at Pharmacia Corporation, prior to its acquisition by Pfizer.

Dr. Durrant is a founding director of a private nanotech oncology company, a board member of two private medical device companies, is currently working with private equity funds and recently started a European specialty pharma company.

Additionally, the Board appointed Elliot Maza, JD, CPA (inactive) as an independent director and Chairman of the Audit Committee.

The Board reorganization was in conjunction with the resignations of two directors and the appointment of Mr. Berdugo, who is leaving the Board in order to become the new Chief Financial Officer.

Mr. Maza currently is Chairman, Chief Executive Officer and CFO at Intellect Neurosciences Inc.

Previously, Mr. Maza was Chief Executive Officer and CFO at Biozone Pharmaceuticals, Inc. and Chief Financial Officer of Emisphere Technologies Inc.

Mr. Maza has been a Partner, Transaction Advisory Services, at Ernst & Young, LLP.

He began his professional career as an Attorney at Sullivan and Cromwell in New York and then in Investment banking as Vice President of Structured Finance in the Fixed Income divisions of Goldman Sachs & Co., J.P. Morgan Securities, Inc. and BT Securities Corporation where he developed and marketed structured finance and derivative based transactions.

He has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee.

Mr. Maza is a registered attorney and a licensed C.P.A. (inactive) in the states of New York and New Jersey.

Mr. Maza received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.